Scott Kellen

Kips Bay Medical, Inc. was a medical device company focused on developing, manufacturing and commercializing its proprietary external saphenous vein support technology for use in coronary artery bypass grafting surgery. Its product, eSVS MESH, was a nitinol mesh sleeve that was placed over the saphenous vein graft during CABG surgery and is designed to constrict the vein and prevent expansion of the vein graft and resulting injury due to increased pressure. The company was founded by Manuel A. Villafaña on May 1, 2007 and was headquartered in Minneapolis, MN.

ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support.

Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY.

Transoma Medical, Inc., headquartered in St. Paul, Minnesota, is a medical technology company engaged in developing, manufacturing and distributing implantable, wireless diagnostic and monitoring systems. Transoma is focused specifically on diagnostic and monitoring technology and dedicated to providing physicians with information needed to accurately and quickly diagnose unexplained, infrequent symptoms and to monitor changing, often asymptomatic complex arrhythmias. Transoma has an extensive technology platform based on more than 20 years experience in developing implantable wireless diagnostic systems for use in biomedical research. These innovative tools have played a key role in drug discovery, pre-clinical evaluation of safety and efficacy, and other academic and government basic research. Customers have turned to DSI for more accurate, timely physiological data, highly humane research practices, and faster times to market. In 2003 the Patient Management division was formed utilizing this proven technology platform and paving the way for the formation of Transoma Medical.